| 2.34 -0.13 (-5.26%) | 11-05 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 3.08 |
1-year : | 3.48 |
| Resists | First : | 2.64 |
Second : | 2.98 |
| Pivot price | 2.53 |
|||
| Supports | First : | 2.09 |
Second : | 1.74 |
| MAs | MA(5) : | 2.58 |
MA(20) : | 2.5 |
| MA(100) : | 2.51 |
MA(250) : | 2.57 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 37.7 |
D(3) : | 53.1 |
| RSI | RSI(14): 42.8 |
|||
| 52-week | High : | 4.19 | Low : | 1.87 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ LSTA ] has closed above bottom band by 21.0%. Bollinger Bands are 36.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.45 - 2.46 | 2.46 - 2.47 |
| Low: | 2.07 - 2.09 | 2.09 - 2.1 |
| Close: | 2.32 - 2.34 | 2.34 - 2.36 |
Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. The company was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. on September 15, 2022. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Tue, 04 Nov 2025
Lisata Therapeutics (LSTA) Showcases Promising Preclinical Data at Industry Conference - GuruFocus
Tue, 04 Nov 2025
Lisata Therapeutics Inc expected to post a loss of 53 cents a share - Earnings Preview - TradingView
Tue, 04 Nov 2025
Lisata Therapeutics reports preclinical data showing certepetide’s potential to enhance cancer drug delivery - Proactive financial news
Tue, 04 Nov 2025
Lisata (Nasdaq: LSTA) cites ADC results: certepetide improved penetration and efficacy - Stock Titan
Tue, 04 Nov 2025
Lisata Therapeutics Highlights Positive Preclinical Data of - GlobeNewswire
Thu, 30 Oct 2025
Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025 - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 9 (M) |
| Held by Insiders | 7.26e+006 (%) |
| Held by Institutions | 19.8 (%) |
| Shares Short | 15 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.083e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -6 % |
| Return on Assets (ttm) | 954.2 % |
| Return on Equity (ttm) | -38.8 % |
| Qtrly Rev. Growth | 1.07e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -61.93 |
| EBITDA (p.s.) | 1.02885e+006 |
| Qtrly Earnings Growth | -2.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -16 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.04 |
| Price to Cash Flow | 0.99 |
| Dividend | 0 |
| Forward Dividend | 19560 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|